5:59 PM
Aug 05, 2014
 |  BC Extra  |  Company News

Cytori slides after hours on trial halt

Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA) fell $0.52 (25%) to $1.58 in early after-hours trading on Tuesday after halting enrollment in the U.S. Phase II ATHENA and ATHENA II trials evaluating its adipose-derived stem and regenerative cells (ADRCs). Cytori said it decided to halt...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >